glp-1 digital health startups platforms What's next for innovation: A primer on the race reshaping pharma and chronic disease care The unknown trajectory of GLP-1 – 👎 The GLP-1 startup making

The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimers disease: Acting separately or synergistically

Attention is also paid to the effect of antioxidants to alleviate the level of oxidative stress, which is a common denominator of various chronic diseases such as neurological disorders, cancer, cardiovascular, renal, lung, metabolic, neurological, psychiatric, and other diseases

To ensure people currently taking dulaglutide and liraglutide can continue to access these medicines, new initiations are restricted to people with type 2 diabetes who are high-risk and have no other appropriate treatment options

This work can be further enhanced with prospective real-world evidence (RWE) non-interventional studies to support payer conversations and publication plans

Ghanemi A, Melouane A, Yoshioka M, St-Amand J